SCHEMBL7367001

SCHEMBL7367001

O=C(O)C(O)(CO)C(Cl)(Cl)Cl

nearest known ligand 0.40

Predicted protein targets (top 5)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 3/20 0.40
TSHR P16473 2/20 0.40
TP53 P04637 1/20 0.40
ACLY P53396 2/20 0.36
TET2 Q6N021 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL3367518 0.76 ALDH1A1 (0.38) ALDH1A1TSHRTP53ACLYTET2
SCHEMBL8595585 0.76 THRB (0.32)
SCHEMBL2125611 0.74 ACLY (0.37) ALDH1A1TSHRACLYTET2
SCHEMBL7123847 0.72 TSHR (0.45) ALDH1A1TSHRACLYTET2
SCHEMBL28305996 0.72 ACLY (0.37) ALDH1A1TSHRTP53ACLYTET2
SCHEMBL1495773 0.71
SCHEMBL9747113 0.70 ACLY (0.34) ALDH1A1TSHRACLYTET2
SCHEMBL259584 0.67
SCHEMBL557277 0.67 ALDH1A1 (0.40) ALDH1A1TSHRTP53
Trichloroacetic Acid SCHEMBL11719563 0.65 ALDH1A1 (0.62) ALDH1A1TSHRTP53

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 44 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
CN-108084026-A A kind of new method of the chlorogenic acid extracting from Cortex Eucommiae 大兴安岭林格贝寒带生物科技股份有限公司 2018-05-29 CN claimed
CN-103059069-B A kind of process of extracting general flavone from wild walking fern Daxing'an Mountainrange Lin Gebei psychrophile Science and Technology Co., Ltd. (CN) 2016-05-25 CN claimed
CN-103059069-A Novel technique method for extracting general flavone from wild walking fern DAXINGANLING LINGONBERRY ORGANIC FOODSTUFFS CO LTD 2013-04-24 CN claimed
CN-117866035-A Triterpene saponin compound in golden camellia and preparation method thereof 广西大学 2024-04-12 CN disclosed
EP-3344622-B1 GUANIDINE SUBSTITUTED, FUSED 1H-IMIDAZO[4,5-C]PYRIDINE COMPOUNDS USEFUL IN THE TREATMENT OF VIRAL AND NEOPLASTIC DISEASES 3M INNOVATIVE PROPERTIES CO (US) 2021-07-07 EP disclosed
EP-3344623-B1 IMIDAZO[4,5-C]RING COMPOUNDS CONTAINING SUBSTITUTED GUANIDINE GROUPS 3M INNOVATIVE PROPERTIES CO (US) 2021-02-17 EP disclosed
US-10487081-B2 Guanidine substituted imidazo[4,5-c] ring compounds 3M INNOVATION PROPERTIES COMPANY (US) 2019-11-26 US disclosed
EP-2397488-B1 DIPEPTIDE MIMETICS OF NGF AND BDNF NEUROTROPHINS FEDERAL STATE BUDGETARY INSTITUTION RES ZAKUSOV INSTITUTE OF PHARMACOLOGY (RU) 2019-03-27 EP disclosed
US-20190055241-A1 GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS SOLVENTUM INTELLECTUAL PROPERTIES COMPANY 2019-02-21 US disclosed
US-10150768-B2 Guanidine substituted imidazo[4,5-c] ring compounds 3M INNOVATIVE PROPERTIES COMPANY (US) 2018-12-11 US disclosed
US-10118925-B2 Imidazo[4,5-c] ring compounds containing substituted guanidine groups 3M INNOVATIVE PROPERTIES COMPANY (US) 2018-11-06 US disclosed
EP-0171677-B1 NOVEL ANTHRACYCLINE ANTIBIOTICS Sanraku Incorporated (JP) 1988-11-30 EP disclosed
EP-0230053-A2 7-(Substituted)piperazinyl-1-ethyl-6-fluoro-1,4-dihydro-4-oxo-3-quinolinecarboxylic acids AMERICAN CYANAMID COMPANY (US) 1987-07-29 EP disclosed
US-4612371-A Anthracycline antibiotics SANRAKU INCORPORATED (JP) 1986-09-16 US disclosed
EP-0171677-A1 Novel anthracycline antibiotics Sanraku Incorporated (JP) 1986-02-19 EP disclosed
US-4439425-A IMMUNOLOGY CIBA-GEIGY CORPORATION (US) 1984-03-27 US disclosed
EP-0026849-B1 PROCESS FOR PRODUCING ANTHRACYCLINE GLYCOSIDES SANRAKU-OCEAN CO., LTD. (JP) 1983-12-07 EP disclosed
US-4337312-A CONVERSION OF AKLAVINONE AND RHODOMYCINONE TO DAUNOMYCIN AND BAUMYCIN ANTIBIOTICS SANRAKU-OCEAN CO., LTD. (JP) 1982-06-29 US disclosed
EP-0026849-A1 Process for producing anthracycline glycosides SANRAKU-OCEAN CO., LTD. (JP) 1981-04-15 EP disclosed
US-4128540-A Pyroglutamyl-histidyl-tryptophanyl-seryl-tyrosyl hydrazides PARKE, DAVIS & COMPANY (US) 1978-12-05 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-10150768-B2 Guanidine substituted imidazo[4,5-c] ring compounds IFNG, IL4, IRF3 ALDH1A1 2056/4885TSHR 2575/4885TP53 90/4885
US-10487081-B2 Guanidine substituted imidazo[4,5-c] ring compounds IFNG, IRF3, IL4 ALDH1A1 2282/4885TSHR 2622/4885TP53 79/4885
US-10118925-B2 Imidazo[4,5-c] ring compounds containing substituted guanidine groups IFNG, IRF3, IL4 ALDH1A1 2263/4885TSHR 2746/4885TP53 133/4885
US-20190055241-A1 GUANIDINE SUBSTITUTED IMIDAZO[4,5-c] RING COMPOUNDS IFNG, IRF3, IL4 ALDH1A1 2282/4885TSHR 2622/4885TP53 79/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.